Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ME-401 in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
NCT04533581Phase 2Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Sep 2020
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zandelisib in indolent B-cell non-Hodgkin lymphoma, sponsored by Kyowa Kirin. Started Sep 2020; status: active, not recruiting.
02
Drugs
zandelisib
03
Conditions
indolent B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04533581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04533581.